Takeda Pays Alnylam $20 Million For Gene-Silencing Technology
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceuticals paid U.S.-based Alnylam Pharmaceuticals $20 million for its gene-silencing technology. The information is part of an agreement to transfer RNAi technology from Alnylam to Takeda in exchange for milestone and royalty payments by Takeda, already beyond $120 million. Takeda intends to use the information to develop treatments to block proteins before they can cause a disease or medical condition. (Click here for more
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.